![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2025
Harbeck, N. 
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]
2022
Trapani, D.; Franzoi, M. A.; Burstein, H. J.; Carey, L. A.; Delaloge, S.; Harbeck, N.; Hayes, D. F.; Kalinsky, K.; Pusztai, L.; Regan, M. M.; Sestak, I.; Spanic, T.; Sparano, J.; Jezdic, S.; Cherny, N.; Curigliano, G. und Andre, F.
(2022):
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
In: Annals of Oncology, Bd. 33, Nr. 7: S. 702-712
Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J.
(2022):
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567
2017
Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J. und Pusztai, L.
(2017):
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
In: Annals of Oncology, Bd. 28, Nr. 1: S. 128-135
2016
Pusztai, L.; Shi, W.; Jiang, T.; Nuciforo, P.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Rimm, D.; Hatzis, C.; Pena, L. de la; Armour, A.; Piccart-Gebhart, M. und Baselga, J.
(2016):
Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies.
In: Cancer Research, Bd. 76